Photo by nci from unsplash
Cardenas-de la Garza et al 1 ask a reasonable question that nowadays likely resonates in many rheumatological practices: “Should we screen our patients who start biologics for SARS-CoV-2?” As so… Click to show full abstract
Cardenas-de la Garza et al 1 ask a reasonable question that nowadays likely resonates in many rheumatological practices: “Should we screen our patients who start biologics for SARS-CoV-2?” As so often in medicine, the question is easily asked but is more difficult to answer. First of all, screening implies the availability of a diagnostic test to be applied in a patient that does not have symptoms (yet). For SARS-CoV-2, we have two types of tests available: the PCR test, known as the ‘swab-test’, which proves the presence of the virus, and the antibody test, which proves the presence of …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!